Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors.
In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease.
Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A.
The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx.
Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 25 | 0.84 Increased by +496.50% | 0.36 Increased by +132.94% |
| Nov 6, 24 | 0.29 Decreased by -38.30% | 0.35 Decreased by -17.14% |
| Aug 8, 24 | 0.31 Increased by +3.33% | 0.33 Decreased by -6.06% |
| May 2, 24 | 0.29 Increased by +480.00% | 0.14 Increased by +107.14% |
| Feb 14, 24 | 0.14 Increased by +16.67% | 3.99 Decreased by -96.49% |
| Nov 7, 23 | 0.47 Decreased by -11.32% | 3.14 Decreased by -85.03% |
| Aug 3, 23 | 0.30 Decreased by -26.83% | 2.18 Decreased by -86.24% |
| May 10, 23 | 0.05 Decreased by -54.55% | 0.65 Decreased by -92.31% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 5.54 B Increased by +16.78% | 1.27 B Decreased by -40.54% | Increased by +22.85% Decreased by -49.08% |
| Jun 30, 24 | 5.40 B Increased by +28.68% | 1.41 B Increased by +3.76% | Increased by +26.06% Decreased by -19.37% |
| Mar 31, 24 | 4.14 B Increased by +45.16% | 1.32 B Increased by +530.95% | Increased by +31.98% Increased by +334.65% |
| Dec 31, 23 | 4.68 B Decreased by -10.50% | 640.00 M Increased by +9.59% | Increased by +13.68% Increased by +22.45% |
| Sep 30, 23 | 4.74 B Increased by +16.08% | 2.13 B Decreased by -17.54% | Increased by +44.88% Decreased by -28.96% |
| Jun 30, 23 | 4.20 B Increased by +32.76% | 1.36 B Decreased by -28.24% | Increased by +32.32% Decreased by -45.95% |
| Mar 31, 23 | 2.85 B Increased by +34.69% | 210.00 M Decreased by -54.84% | Increased by +7.36% Decreased by -66.47% |
| Dec 31, 22 | 5.23 B Increased by +99.58% | 584.00 M Decreased by -18.44% | Increased by +11.17% Decreased by -59.13% |